Lexicon Pharmaceuticals, Inc. (LXRX) Announces Quarterly Earnings Results

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.20. The business had revenue of $23 million for the quarter, compared to analysts’ expectations of $15.56 million. Lexicon Pharmaceuticals had a negative net margin of 11.87% and a negative return on equity of 9.46%. The business’s quarterly revenue was down 81.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.76 EPS.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) traded up 1.68% during mid-day trading on Friday, hitting $13.93. 948,365 shares of the stock traded hands. The firm has a 50 day moving average of $15.26 and a 200 day moving average of $15.83. Lexicon Pharmaceuticals has a 12 month low of $11.52 and a 12 month high of $19.62. The company’s market cap is $1.45 billion.

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

TRADEMARK VIOLATION NOTICE: “Lexicon Pharmaceuticals, Inc. (LXRX) Announces Quarterly Earnings Results” was first posted by Web Breaking News and is the sole property of of Web Breaking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at http://www.webbreakingnews.com/2017/03/07/lexicon-pharmaceuticals-inc-lxrx-releases-quarterly-earnings-results-beats-estimates-by-0-21-eps.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. Oxford Asset Management raised its stake in Lexicon Pharmaceuticals by 18.6% in the second quarter. Oxford Asset Management now owns 387,383 shares of the biopharmaceutical company’s stock valued at $5,559,000 after buying an additional 60,623 shares in the last quarter. American Century Companies Inc. purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at approximately $2,194,000. Stifel Financial Corp purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at approximately $890,000. Schwab Charles Investment Management Inc. raised its stake in Lexicon Pharmaceuticals by 100.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 305,203 shares of the biopharmaceutical company’s stock valued at $4,380,000 after buying an additional 152,735 shares in the last quarter. Finally, First Mercantile Trust Co. raised its stake in Lexicon Pharmaceuticals by 85.2% in the third quarter. First Mercantile Trust Co. now owns 19,813 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 9,113 shares in the last quarter.

Several brokerages have commented on LXRX. Citigroup Inc set a $24.00 price target on shares of Lexicon Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, December 25th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 17th. Cowen and Company restated a “market perform” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, December 23rd. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, February 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $25.14.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

5 Day Chart for NASDAQ:LXRX

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.